At Source BioScience, we provide a comprehensive portfolio of clinical genomic and molecular tests that support precision oncology across a range of cancers.
Supporting Personalised Cancer Care
Our clinical genomic testing portfolio is designed to support:
We work in partnership with healthcare providers across the NHS and private sector to integrate precision oncology testing into routine clinical practice.
Our Services
Our oncology testing portfolio is designed to meet the needs of routine clinical care, referral testing, and specialist cancer services. All assays are delivered through ISO 15189-accredited laboratories, using validated methods and robust quality assurance frameworks.
Prostate Cancer
Multivariable risk assessment for clinically significant prostate cancer prior to biopsy
Breast Cancer
- Predictive and prognostic genomic biomarker guiding adjuvant bisphosphonate use in early ER-positive, HER2-negative breast cancer
- Targeted mutation testing and NGS panels to assess inherited cancer risk
Bladder Cancer
Non-invasive genomic test for surveillance of non-muscle-invasive bladder cancer
Lung Cancer
- Blood-based risk stratification for patients with indeterminate pulmonary nodules
- Targeted mutation testing and NGS panels to assess inherited cancer risk
Partnering with Your Clinic to Enhance Patient Care
Source Genomics provides clinics and healthcare providers with access to novel biomarker-driven tests across multiple cancer types. Partnering with us will enable access to:
Source Genomics works in partnership with healthcare providers to integrate validated molecular and genomic oncology tests that support clinical decision-making across the cancer pathway, from early risk stratification through to therapy selection. Contact us to speak with our clinical specialists or to request detailed information on test implementation.